Sengenics Corporation Announces New French Distributor

Sengenics Strengthens Strategy to Enable Wider Access to Patented Protein Microarray Technology with the Launch of the Sengenics i-Ome® Protein Array Kit

Sengenics today announced the commercial launch of the i-Ome® Protein Array Kit. The i-Ome® Protein Array Kit contains slide-based, high density protein microarrays, comprised of 1600+ immobilized, full-length, correctly folded human proteins. The new product brings the KREXTM technology within reach to deliver a best-in-class autoantibody discovery tool and to enable researchers focused on autoantibody biomarker identification in the autoimmune disease, immuno-oncology and neuroinflammation fields.

“The Sengenics i-Ome® Protein Array Kit offers greater access to exceptional autoantibody discovery power and operating efficiency, unlocking highly multiplexed applications,” said Dr. Arif Anwar, Sengenics CEO. “Bearing in mind our customers’ needs, Sengenics reimagined the kit with innovative solutions that extend the unmatched accuracy and reproducibility of KREXTM technology to fuel more in-depth research across the autoimmune, immuno-oncology and neurology fields.”

To learn more, please visit https://sengenics.com/products-and-services/

About Sengenics

Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.

Read full press release at businesswire.com 

Sengenics Continues to Expand Global Footprint with New Distribution Agreements in the Asia-Pacific Region

Sengenics, THE Functional Proteomics Company, is pleased to announce the signing of new sales and marketing agreements with major distributors in East Asia to make our suite of products and services more widely accessible to customers in the region. Our new partners will market and provide full support for Sengenics’ proprietary technology to pharmaceutical, biotech and academic institutions in APAC.

Sengenics leverages its patented KREX protein folding technology to discover autoantibody biomarker signatures for patient stratification, drug response prediction, and development of companion diagnostics.

“We are thrilled and excited to strengthen and expand our reach in the APAC region, as we have finalized sales and marketing agreements with 5 major distributors. Our main purpose, as a company, is to translate our one-of-a-kind proteomics technology to enable precision medicine and early disease detection with the ultimate goal of improving both patient outcomes and healthcare expenditures. With these agreements in place, our unique technology will be making a difference very quickly in this region and across the globe,” said Sengenics Vice President of Global Sales and Marketing, Mark D. Quigley.

About the distributors

Shanghai Universal Biotech, a leading life sciences distributor in China with multiple offices across the country and a lab facility in Shanghai, is a premier antibody supplier and expert in a variety of proteomics products.

Filgen, Inc. is a major distributor of life science equipment, reagents and software in Japan for both academic and pharma/biotech markets.

Gene On Biotech is a leading microarray service provider in South Korea that specializes in antibody microarray, protein microarray, drug candidate identification, and epitope mapping services.

AllBio Science focuses on providing innovative products and services in the areas of gene sequencing, precision medicine, protein expression, and customized antibodies.

LAB-A-PORTER is the pioneering Hong Kong-based distributor focused on product channeling in scientific research, healthcare, and academia.

About Sengenics

Sengenics is a functional proteomics company that leverages its patented KREX protein folding technology to discover autoantibody biomarker signatures for drug response prediction, patient stratification, and development of companion diagnostics in the areas of oncology, autoimmune disease and neuroinflammatory disease. The company has a global footprint with multiple corporate and research sites across the world with customers and collaborators that include top pharma, biotech and Ivy League academic institutions in North America, Europe and Asia.

Read full press release at businesswire.com 

Sengenics Bolsters Leadership Team with Two New Appointments

Sengenics, the Functional Proteomics Company, today announced the appointment of Daniel Tan as Chief Financial Officer and Mark D. Quigley as Vice President of Global Sales and Marketing. This announcement comes as Sengenics sees continued growth with the planned establishment of a research facility in Massachusetts, USA.

Daniel Tan is a highly accomplished Chief Financial Officer having worked senior roles for more than 25 years in audit, corporate finance, strategy and commercial finance at Baker Tilly and Barclays Bank in the UK, amongst others. Daniel has led a number of IPO assignments on the London Stock Exchange and AIM as well as due diligence engagements on mergers and acquisitions. In his new role, Daniel will drive Sengenics’ financial and strategic growth plans.

Mark D. Quigley joins Sengenics with decades of technical sales and business development experience in the life sciences space. Prior to this, Mark held various senior positions and has led high-performance sales teams in North America at MilliporeSigma (Merck KGaA) and Abcam. Mark is a recognised leader of cross-functional teams with outstanding sales leadership and significant experience in driving organisational change and business transformation. Mark will be responsible for leading Sengenics’ global sales and marketing activities.

Dr Arif Anwar, CEO of Sengenics, said, “We are delighted to have Daniel and Mark join us in these critical leadership positions in finance and sales. They will both be instrumental in implementing our forward strategy to globalise our business with an increasing emphasis on North American operations.”

About Sengenics

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Read full press release at businesswire.com